In This Issue

• News from the IASLC Tobacco Control Committee

Editorials

• Smoking Cessation and Low-Dose Computed Tomography Screening: A Necessary Pair
• DDR Alterations as a Surrogate Marker for TMB in SCLC — Use it or Lose it?
• Micronodules Detected on Lung Cancer Screening CT Scans

Editorial - Lung Cancer Worldwide

• Lung Cancer in Chile

Commentary

• Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non–Small Cell Lung Cancer

Review Article

• Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018

Original Articles

• A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program
• Micronodules Detected on Computed Tomography During the National Lung Screening Trial: Prevalence and Relation to Positive Studies and Lung Cancer
• Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib
• Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
• Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer
• Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung
• Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium
• Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
• Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC
• Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
• DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
• Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations

Brief Reports

• Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial
• MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
•  

Image of the Month

• Esophageal Squamous Cell Carcinoma Involving the Lip, Back and Hip

Case Report

• Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports